FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3021494038> ?p ?o ?g. }

• W3021494038 endingPage "711" @default.
• W3021494038 startingPage "702" @default.
• W3021494038 abstract "Programmed death-ligand 1 (PD-L1) expression is associated with clinical outcomes of epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (ADC) treated with tyrosine kinase inhibitors (TKIs). However, whether PD-L1 expression plays a role in anaplastic lymphoma kinase (ALK)-positive lung ADC is unknown. We aimed to evaluate the impact of PD-L1 in patients with ALK-positive lung ADC receiving crizotinib.PD-L1 expression was identified by immunohistochemistry (IHC). Reverse transcriptase-polymerase chain reaction was used for ALK variant detection, and immunofluorescence-based multiplex staining was applied for exploring immune cells in tumor microenvironments.A total of 78 patients with ALK-positive advanced ADC were enrolled in our study, of whom 52 received crizotinib. Compared with EGFR/ALK wild-type tumors, PD-L1 expression was lower in ALK-positive ADC. ALK fusion variants were identified in 32 patients, and those with variant 3 and 5 (short variants) had higher PD-L1 expression than those with other variants. The crizotinib objective response rate (ORR) and progression-free survival (PFS) was better in tumors with negative PD-L1 expression (ORR/PFS in PD-L1 0% vs. 1%-49% vs. 50%-100%: 60.7%/11.8 months vs. 38.5%/6.5 months vs. 36.4%/4.0 months, p = .007/.022). The multivariate Cox proportional hazards model revealed that PD-L1 0% (vs. ≥1%) was an independent factor for longer PFS (adjusted hazard ratio 0.322, 95% confidence interval 0.160-0.650, p = .002). Multiplex IHC in three cases showed a varied extent of immune cell infiltrations in tumors with different PD-L1 expression.Positive PD-L1 expression was associated with unfavorable clinical outcomes in patients with ALK-positive lung ADC receiving crizotinib.Not all lung adenocarcinoma with sensitizing driver mutations experienced durable responses to small-molecule tyrosine kinase inhibitors (TKIs). Similar to the negative impact of programmed death-ligand 1 (PD-L1) in epidermal growth factor receptor mutant tumors treated with TKIs, this study demonstrated that positive PD-L1 expression was also associated with worse response rate and shorter progression-free survival of anaplastic lymphoma kinase (ALK)-positive adenocarcinoma treated with crizotinib. Among different ALK fusion partners, tumors with short variants (V3 and V5) had higher PD-L1 compared with long variants (V1, V2, and V6). Testing PD-L1 before initiating crizotinib for ALK-positive lung cancer could be a simple method to provide important prognostic information." @default.
• W3021494038 created "2020-05-13" @default.
• W3021494038 creator A5002458975 @default.
• W3021494038 creator A5009000893 @default.
• W3021494038 creator A5020674154 @default.
• W3021494038 creator A5024849088 @default.
• W3021494038 creator A5036885923 @default.
• W3021494038 creator A5041294713 @default.
• W3021494038 creator A5043946908 @default.
• W3021494038 creator A5044441757 @default.
• W3021494038 creator A5052678985 @default.
• W3021494038 creator A5055074037 @default.
• W3021494038 creator A5055415475 @default.
• W3021494038 creator A5056367345 @default.
• W3021494038 creator A5056944727 @default.
• W3021494038 creator A5070791189 @default.
• W3021494038 creator A5084397879 @default.
• W3021494038 creator A5086926024 @default.
• W3021494038 creator A5087678313 @default.
• W3021494038 date "2020-05-13" @default.
• W3021494038 modified "2023-10-17" @default.
• W3021494038 title "Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib" @default.
• W3021494038 cites W1773771017 @default.
• W3021494038 cites W1982488143 @default.
• W3021494038 cites W2031373281 @default.
• W3021494038 cites W2043696829 @default.
• W3021494038 cites W2050588414 @default.
• W3021494038 cites W2053627244 @default.
• W3021494038 cites W2055402151 @default.
• W3021494038 cites W2071865120 @default.
• W3021494038 cites W2088270805 @default.
• W3021494038 cites W2094903176 @default.
• W3021494038 cites W2099530756 @default.
• W3021494038 cites W2130488043 @default.
• W3021494038 cites W2138619415 @default.
• W3021494038 cites W2151136040 @default.
• W3021494038 cites W2166292499 @default.
• W3021494038 cites W2168635759 @default.
• W3021494038 cites W2198093519 @default.
• W3021494038 cites W2210071992 @default.
• W3021494038 cites W2319183095 @default.
• W3021494038 cites W2339561092 @default.
• W3021494038 cites W2471664064 @default.
• W3021494038 cites W2527905628 @default.
• W3021494038 cites W2538232731 @default.
• W3021494038 cites W2549236974 @default.
• W3021494038 cites W2552750859 @default.
• W3021494038 cites W2560367415 @default.
• W3021494038 cites W2564366019 @default.
• W3021494038 cites W2570618306 @default.
• W3021494038 cites W2572174216 @default.
• W3021494038 cites W2575258963 @default.
• W3021494038 cites W2581996620 @default.
• W3021494038 cites W2603411876 @default.
• W3021494038 cites W2759881380 @default.
• W3021494038 cites W2781180031 @default.
• W3021494038 cites W2781790748 @default.
• W3021494038 cites W2783461788 @default.
• W3021494038 cites W2783722656 @default.
• W3021494038 cites W2789601608 @default.
• W3021494038 cites W2792575938 @default.
• W3021494038 cites W2802395274 @default.
• W3021494038 cites W2884738271 @default.
• W3021494038 cites W2889307896 @default.
• W3021494038 cites W2890523839 @default.
• W3021494038 cites W2890894948 @default.
• W3021494038 cites W2900894054 @default.
• W3021494038 cites W2901340123 @default.
• W3021494038 cites W2916508569 @default.
• W3021494038 cites W2924476045 @default.
• W3021494038 cites W2925446385 @default.
• W3021494038 cites W2946166987 @default.
• W3021494038 cites W2949244813 @default.
• W3021494038 cites W2966461747 @default.
• W3021494038 cites W2990409488 @default.
• W3021494038 cites W2970177775 @default.
• W3021494038 doi "https://doi.org/10.1634/theoncologist.2020-0088" @default.
• W3021494038 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7418350" @default.
• W3021494038 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32386255" @default.
• W3021494038 hasPublicationYear "2020" @default.
• W3021494038 type Work @default.
• W3021494038 sameAs 3021494038 @default.
• W3021494038 citedByCount "17" @default.
• W3021494038 countsByYear W30214940382020 @default.
• W3021494038 countsByYear W30214940382021 @default.
• W3021494038 countsByYear W30214940382022 @default.
• W3021494038 countsByYear W30214940382023 @default.
• W3021494038 crossrefType "journal-article" @default.
• W3021494038 hasAuthorship W3021494038A5002458975 @default.
• W3021494038 hasAuthorship W3021494038A5009000893 @default.
• W3021494038 hasAuthorship W3021494038A5020674154 @default.
• W3021494038 hasAuthorship W3021494038A5024849088 @default.
• W3021494038 hasAuthorship W3021494038A5036885923 @default.
• W3021494038 hasAuthorship W3021494038A5041294713 @default.
• W3021494038 hasAuthorship W3021494038A5043946908 @default.
• W3021494038 hasAuthorship W3021494038A5044441757 @default.
• W3021494038 hasAuthorship W3021494038A5052678985 @default.
• W3021494038 hasAuthorship W3021494038A5055074037 @default.

• next